Microsatellite Stable Colorectal Cancer Clinical Trial
Official title:
An Open-label, Single-arm, Phase 1b Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination With Pembolizumab in Patients With Advanced or Progressive Microsatellite Stable (MSS) Colorectal Cancer (CRC)
Verified date | October 2023 |
Source | Arrys Therapeutics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will be conducted in adult participants diagnosed with any form of an advanced or progressive MSS CRC for which 1st and 2nd line standard therapy (at least one of which contained fluorouracil) is no longer effective or is intolerable. This is a phase 1b, multi-center, open label study designed to assess safety and tolerability of grapiprant in combination with pembrolizumab, to determine the recommended phase 2 dose (RP2D) with pembrolizumab, and to evaluate and characterize the PK of grapiprant alone and in combination with pembrolizumab. Disease response, pharmacodynamics, and response biomarkers will also be assessed.
Status | Completed |
Enrollment | 54 |
Est. completion date | March 7, 2023 |
Est. primary completion date | March 7, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Key Inclusion Criteria: - Male and female adult patients 18 years of age or older on day of signing informed consent. - Patients must have a histologically confirmed advanced, metastatic, or progressive Microsatellite Stable (MSS) Colorectal Cancer (CRC) per institutional standards. - Patient has received at least two prior lines of therapy for advanced or metastatic CRC, at least one of which included fluorouracil. - Highly effective birth control. - Measurable disease. - Accessible tumor that can be safely accessed for multiple core biopsies and patient is willing to provide tissue from newly obtain biopsies before and during treatment. - Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. - Adequate organ function. - Able to swallow and absorb oral tablets. Key Exclusion Criteria: - Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor - Current use of NSAIDs, COX-2 inhibitors and aspirin products within 3 days (preferably 7 days) before treatment initiation or at anytime during the study unless used for management of AE. - History of severe hypersensitivity reactions to chimeric or humanized antibodies - Has received prior systemic anticancer therapy including investigational agents within 4 weeks prior to treatment, or 5 half-lives, whichever is shorter. - Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug. - Known additional malignancy that is progressing or has required active treatment within the past 3 years. - Known active CNS metastases and/or carcinomatous meningitis. - Active autoimmune disease that has required systemic treatment in past 2 years. - History of non-infectious pneumonitis that required steroids or has current pneumonitis. - Active infection requiring systemic therapy. - Recent (within the last 12 months) or current GI ulcer, colitis or non-immune colitis. - Known history of human immunodeficiency virus (HIV) infection, Hepatitis B, or active Hepatitis C virus infection. - Clinically significant (i.e. active) cardiovascular disease - Allogeneic tissue/solid organ transplant - Medical conditions requiring concomitant administration of strong CYP3A4 or P glycoprotein inhibitors or inducers. |
Country | Name | City | State |
---|---|---|---|
United States | University of Colorado Denver-Anschutz Medical Campus | Aurora | Colorado |
United States | Sarah Cannon Research Institute, LLC (SCRI) | Nashville | Tennessee |
United States | Mayo Clinic Cancer Center - Scottsdale | Phoenix | Arizona |
United States | New Experimental Therapeutics of San Antonio-NEXT Oncology | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
Arrys Therapeutics | Merck Sharp & Dohme LLC |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and tolerability of grapiprant alone and in combination with pembrolizumab | Number of incidence, severity, and duration of treatment emergent adverse events using CTCAE v5.0 | Up to 90 days after the end of treatment (average of 7 months) | |
Primary | Define the recommended phase 2 dose (RP2D) of grapiprant combined with pembrolizumab | Number, incidence and severity of treatment related adverse events as assessed by CTCAE 5.0 | Through Cycle 1 (21 days) | |
Secondary | Overall Response Rate (ORR) | Proportion of participants who achieved PR or better during the study per RECIST 1.1 | 7 months | |
Secondary | Duration of Response (DOR) | Time when criteria for response are met, to the first documentation of relapse or progression | 7 months | |
Secondary | Progression -free survival (PFS) | Participants who discontinue treatment without disease progression | Up to 12 months | |
Secondary | Disease control rate (DCR) | Percentage of participants who achieved a CR, PR and stable disease | 7 months | |
Secondary | Overall survival (OS) | Date of study drug to date of death due to any cause. If no documentation of death at time of the analysis will be censored as of the date last known to be alive, or the data cutoff date, whichever is earlier. | Up to 2 years from start of study drug. | |
Secondary | Duration of treatment (DOT) | Time of duration on treatment | 7 months | |
Secondary | Serum tumor marker changes | Assess changes in serum tumor markers including but not limited to carcinoembryonic antigen (CEA), when appropriate (eg. CA-19.9, CA125, and lactate dehyrogenase (LDH)) with disease response. | 7 months | |
Secondary | Pharmacodynamic immune effects in paired tumor biopsies | Assess changes in tumor infiltrating helper T cells, cytotoxic T cells and regulatory monocyte/macrophages with study drug treatment | predose through cycle 3 (each cycle is 21 days) | |
Secondary | PGEM as a pharmacodynamic and predictive biomarker | Evaluate disease response in all evaluable participants and in those with a positive initial assessment of Urine prostaglandin E2 metabolite (PGEM) | PreScreening through 7 months | |
Secondary | PK of grapiprant: Tmax | First time to reach maximum [peak] observed plasma concentration | Safety Run-in (7 days); Days 1 and 2 of first 2 cycles (every 21 days), followed by Day 1 of every even cycle beginning with cycle 4 (every 42 days) through end of treatment (average of 4 months) | |
Secondary | PK of grapiprant: AUC0 last | Area under the plasma concentration time curve from time 0 to the end of the dosing interval (AUC0 last) | Safety Run-in (7 days); Days 1 and 2 of first 2 cycles (every 21 days), followed by Day 1 of every even cycle beginning with cycle 4 (every 42 days) through end of treatment (average of 4 months). | |
Secondary | Plasma decay half-life (t1/2) | Measurement of half-life of grapiprant after dosing | Safety Run-in (7 days); Days 1 and 2 of first 2 cycles (every 21 days), followed by Day 1 of every even cycle beginning with cycle 4 (every 42 days) through end of treatment (average of 4 months) | |
Secondary | Apparent oral clearance (CL/F) | Rate of elimination of the drug from plasma after oral administration | Safety Run-in (7 days); Days 1 and 2 of first 2 cycles (every 21 days), followed by Day 1 of every even cycle beginning with cycle 4 (every 42 days) through end of treatment (average of 4 months) | |
Secondary | Peak to trough ratio | Measure how drug effect is sustained over dose interval | Safety Run-in (7 days); Days 1 and 2 of first 2 cycles (every 21 days), followed by Day 1 of every even cycle beginning with cycle 4 (every 42 days) through end of treatment (average of 4 months) | |
Secondary | Observed accumulation ratio | Relationship between the dosing interval and the rate of elimination for the drug. | Safety Run-in (7 days); Days 1 and 2 of first 2 cycles (every 21 days), followed by Day 1 of every even cycle beginning with cycle 4 (every 42 days) through end of treatment (average of 4 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03891953 -
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Recruiting |
NCT04895709 -
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03104439 -
Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02060188 -
A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread
|
Phase 2 | |
Terminated |
NCT04301011 -
Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04332653 -
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT04060342 -
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
|
Phase 1 | |
Not yet recruiting |
NCT06444815 -
A Study of VET3-TGI in Patients With Solid Tumors
|
Phase 1 | |
Completed |
NCT03473925 -
Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)
|
Phase 2 |